Wouter Hoefsloot

4.2k total citations
70 papers, 1.7k citations indexed

About

Wouter Hoefsloot is a scholar working on Epidemiology, Infectious Diseases and Small Animals. According to data from OpenAlex, Wouter Hoefsloot has authored 70 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Epidemiology, 46 papers in Infectious Diseases and 25 papers in Small Animals. Recurrent topics in Wouter Hoefsloot's work include Mycobacterium research and diagnosis (52 papers), Tuberculosis Research and Epidemiology (43 papers) and Infectious Diseases and Mycology (25 papers). Wouter Hoefsloot is often cited by papers focused on Mycobacterium research and diagnosis (52 papers), Tuberculosis Research and Epidemiology (43 papers) and Infectious Diseases and Mycology (25 papers). Wouter Hoefsloot collaborates with scholars based in Netherlands, United States and Sweden. Wouter Hoefsloot's co-authors include Jakko van Ingen, Martin J. Boeree, Dick van Soolingen, P.N.R. Dekhuijzen, Wiel C.M. de Lange, Roland Diel, Sanne M.H. Zweijpfenning, Marc Lipman, Cecile Magis‐Escurra and Sarah Bendien and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and CHEST Journal.

In The Last Decade

Wouter Hoefsloot

68 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wouter Hoefsloot Netherlands	22	1.2k	1.0k	582	207	183	70	1.7k
Sheng‐Wei Pan Taiwan	15	356 0.3×	338 0.3×	66 0.1×	19 0.1×	161 0.9×	74	770
Evan Tzanis United States	23	392 0.3×	350 0.3×	51 0.1×	24 0.1×	208 1.1×	68	1.6k
Michael Luther United States	20	596 0.5×	460 0.5×	65 0.1×	22 0.1×	302 1.7×	35	1.2k
Wei Shu China	16	340 0.3×	451 0.4×	29 0.0×	17 0.1×	297 1.6×	72	861
J. Nicolau France	12	396 0.3×	293 0.3×	30 0.1×	11 0.1×	11 0.1×	24	915
Frédéric‐Antoine Dauchy France	16	206 0.2×	247 0.2×	51 0.1×	10 0.0×	165 0.9×	42	701
Vinod Kumar Gupta India	17	231 0.2×	117 0.1×	41 0.1×	15 0.1×	149 0.8×	114	960
Dennis Riff United States	20	1.1k 0.9×	274 0.3×	25 0.0×	12 0.1×	618 3.4×	46	2.2k
Philip Abraham India	22	369 0.3×	297 0.3×	14 0.0×	49 0.2×	685 3.7×	99	1.6k
Lena Hjelte Sweden	24	253 0.2×	108 0.1×	67 0.1×	12 0.1×	176 1.0×	86	1.9k

Countries citing papers authored by Wouter Hoefsloot

Since Specialization

Citations

This map shows the geographic impact of Wouter Hoefsloot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wouter Hoefsloot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wouter Hoefsloot more than expected).

Fields of papers citing papers by Wouter Hoefsloot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wouter Hoefsloot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wouter Hoefsloot. The network helps show where Wouter Hoefsloot may publish in the future.

Co-authorship network of co-authors of Wouter Hoefsloot

This figure shows the co-authorship network connecting the top 25 collaborators of Wouter Hoefsloot. A scholar is included among the top collaborators of Wouter Hoefsloot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wouter Hoefsloot. Wouter Hoefsloot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laarhoven, Arjan van, et al.. (2025). Medication adherence in patients with nontuberculous mycobacterial disease. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 40. 100544–100544.

Laarhoven, Arjan van, et al.. (2025). Treatment of nontuberculous mycobacterial pulmonary disease requires a stepwise and multidisciplinary approach. Expert Review of Respiratory Medicine. 19(4). 287–299. 2 indexed citations

Magis‐Escurra, Cecile, Martin J. Boeree, Rob E. Aarnoutse, et al.. (2024). Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease. SHILAP Revista de lepidopterología. 1(6). 279–281. 2 indexed citations

Svensson, Elin M., Lindsey H. M. te Brake, Reinout van Crevel, et al.. (2024). A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease. Journal of Antimicrobial Chemotherapy. 79(12). 3100–3108. 5 indexed citations

Smeenk, Frank W.J.M., Pascal Wielders, Wouter Hoefsloot, et al.. (2024). Elderly patients with tuberculosis in a low-incidence country – Clinical characteristics, inflammation and outcome. Journal of Infection. 89(2). 106200–106200. 5 indexed citations

Raaijmakers, J. A. M., Rob E. Aarnoutse, Elin M. Svensson, et al.. (2024). Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model. Antimicrobial Agents and Chemotherapy. 68(3). e0115723–e0115723. 5 indexed citations

Hoefsloot, Wouter, et al.. (2023). Successful addition of topical antibiotic treatment after surgery in treatment-refractory nontuberculous mycobacterial skin and soft tissue infections. Antimicrobial Agents and Chemotherapy. 67(12). e0078823–e0078823. 3 indexed citations

Schildkraut, Jodie A., J. A. M. Raaijmakers, Rob E. Aarnoutse, et al.. (2023). The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease. Antimicrobial Agents and Chemotherapy. 67(11). e0087423–e0087423. 12 indexed citations

Hoefsloot, Wouter, Roald van der Laan, Marieke Krol, et al.. (2023). Real-world treatment patterns in patients with nontuberculous mycobacterial lung disease in the Netherlands based on medication dispensing data. BMC Pulmonary Medicine. 23(1). 218–218. 4 indexed citations

10.

Zweijpfenning, Sanne M.H., Rob E. Aarnoutse, Martin J. Boeree, et al.. (2023). Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment. CHEST Journal. 165(5). 1082–1092. 18 indexed citations

11.

Boeree, Martin J., Cécile Magis-Escurra, Wouter Hoefsloot, et al.. (2022). Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series. Med. 3(9). 603–611.e2. 11 indexed citations

12.

Maat, Josephine van de, Karin Veerman, Jaap ten Oever, et al.. (2021). Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study. PLoS ONE. 16(3). e0248713–e0248713. 27 indexed citations

13.

Ruth, Mike Marvin, J. A. M. Raaijmakers, Rob E. Aarnoutse, et al.. (2021). Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics. Clinical Microbiology and Infection. 28(3). 448.e1–448.e7. 10 indexed citations

14.

Schildkraut, Jodie A., Jack R. Gallagher, Kozo Morimoto, et al.. (2020). Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respiratory Medicine. 173. 106164–106164. 28 indexed citations

15.

Weg, Cornelia A. M. van de, Jurriaan E.M. de Steenwinkel, Jelle Miedema, et al.. (2019). The tough process of unmasking the slow-growing mycobacterium: case report of Mycobacterium microti infection. Access Microbiology. 2(1). acmi000074–acmi000074. 6 indexed citations

16.

Hoefsloot, Wouter, Lindsey te Brake, Jakko van Ingen, et al.. (2019). High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS ONE. 14(3). e0213718–e0213718. 53 indexed citations

17.

Heijden, Erik H.F.M. van der, et al.. (2018). Image enhancement technology in bronchoscopy: a prospective multicentre study in lung cancer. BMJ Open Respiratory Research. 5(1). e000295–e000295. 6 indexed citations

18.

Heijden, Erik H.F.M. van der, et al.. (2015). High definition bronchoscopy: a randomized exploratory study of diagnostic value compared to standard white light bronchoscopy and autofluorescence bronchoscopy. Respiratory Research. 16(1). 33–33. 15 indexed citations

19.

Hoefsloot, Wouter, Jakko van Ingen, Edgar J.G. Peters, et al.. (2012). Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases. Clinical Microbiology and Infection. 19(5). 432–437. 38 indexed citations

20.

Ingen, Jakko van, Sarah Bendien, Wiel C.M. de Lange, et al.. (2009). Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 64(6). 502–506. 196 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact